Recruiting
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms
NCT07638553· Phase 3· Centre Hospitalier Universitaire de Nīmes· Source
Recruiting
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT07456033· Phase 3· GlaxoSmithKline· Source
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
JAK Inhibitor Dose TAPering Strategy Study
NCT06687551· Phase 4· University Hospital, Toulouse· Source
Recruiting
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
NCT06471465· Phase 3· Institut Cancerologie de l'Ouest· Source
Recruiting
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
NCT05973864· Phase 2· UNICANCER· Source
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
2023-504022-19-01· Phase 3· AstraZeneca AB· Source
Recruiting
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
NCT05532813· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
2023-509340-10-00· Phase 3· OSE Immunotherapeutics· Source
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
2023-503697-21-01· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source
Recruiting
Impact of local tissue inflammation on intramyocardial conduction pathways post percutaneous valve : evaluation by positron emission tomography on exploratory cohort
2024-514587-44-00· Phase 2· Centre Hospitalier Regional Et Universitaire De Brest· Source
Recruiting
FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and platinum as first line treatment in patients with large-cell neuroendocrine carcinomas (LCNECs) of the lung.
2023-506590-35-00· Phase 2· Centre Leon Berard· Source
Recruiting
Amoxicillin alone versus amoxicillin/clavulanate for community-acquired pneumonia in patients aged 65 years or older, and hospitalized in a non-intensive care unit ward: a non-inferiority randomized controlled trial _ CAPTAIN
2023-503645-63-00· Phase 3· Centre Hospitalier Universitaire De Nantes· Source
Active, not recruiting
TocilizuMab discontinuAtion in GIant Cell Arteritis
2023-505515-21-00· Phase 3· Centre Hospitalier Universitaire De Dijon· Source
Recruiting
Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype
NCT06269900· Phase 3· Nantes University Hospital· Source
Active, not recruiting
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
NCT06041386· Phase 4· GlaxoSmithKline· Source
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Study comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid leukemia or myelodysplastic syndrome and receiving an allogeneic stem cell transplantation with an unrelated matched donor after a reduced intensity conditioning regimen
2023-504555-27-00· Phase 3· Assistance Publique Hopitaux De Paris· Source
Active, not recruiting
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803· Phase 3· AstraZeneca· Source
Recruiting
Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets
NCT05627375· Phase 3· Centre Hospitalier Universitaire de Saint Etienne· Source
Recruiting
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
NCT05758831· Phase 3· Rennes University Hospital· Source
Recruiting
Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease
NCT05732727· Phase 3· University Hospital, Tours· Source
Active, not recruiting
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis
NCT05428488· Phase 3· University Hospital, Montpellier· Source
Recruiting
Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
NCT05180825· Phase 2· University Hospital, Strasbourg, France· Source
Active, not recruiting
OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma
2024-512634-15-00· Phase 1/2· LYSARC· Source
Active, not recruiting
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis
NCT04870203· Phase 3· University Hospital, Bordeaux· Source
Active, not recruiting
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156· Phase 3· Geron Corporation· Source
Active, not recruiting
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
NCT03806309· Phase 2· GERCOR - Multidisciplinary Oncology Cooperative Group· Source
Recruiting
A Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular Dystrophy
NCT07856329· Phase 2/3· Genethon· Source
Recruiting
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
NCT04319627· Phase 3· Ottawa Hospital Research Institute· Source
Active, not recruiting
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252· Phase 3· AstraZeneca· Source
Active, not recruiting
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772· Phase 3· Acerta Pharma BV· Source
Recruiting
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
NCT03583710· Phase 3· M.D. Anderson Cancer Center· Source
Active, not recruiting
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
NCT03323476· Phase 3· Centre Hospitalier Departemental Vendee· Source
Recruiting
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224· Phase 2· Apollomics Inc.· Source
Active, not recruiting
Paediatric Hepatic International Tumour Trial
NCT03017326· Phase 3· University of Birmingham· Source
Completed
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT03079011· Phase 3· UNICANCER· Source
Active, not recruiting
Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma
NCT00470223· Phase 3· UNICANCER· Source